Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2021 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
[POEMS-syndrome].
Arkhipov IE, Vergunova IY, Malkova NA, Korobko DS. Arkhipov IE, et al. Among authors: vergunova iy. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(7. Vyp. 2):15-21. doi: 10.17116/jnevro202312307215. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37560829 Russian.
[Susac syndrome, review and clinical case].
Vergunova IY, Malkova NA, Korobko DS. Vergunova IY, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):52-57. doi: 10.17116/jnevro20191192252. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31156242 Review. Russian.
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
Evdoshenko E, Stepanova A, Shumilina M, Davydovskaya M, Khachanova N, Neofidov N, Kalinin I, Popova E, Dubchenko E, Pozhidaeva N, Volkov A, Sivertseva S, Prilenskaya A, Malkova N, Korobko D, Vergunova I, Shchur S, Makshakov G. Evdoshenko E, et al. Among authors: vergunova i. PLoS One. 2019 May 28;14(5):e0217303. doi: 10.1371/journal.pone.0217303. eCollection 2019. PLoS One. 2019. PMID: 31136608 Free PMC article.